The M1/M4 preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia-Reference-Cited by-同舟云学术

The M1/M4 preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia

Published:2011-10 Issue:9 Volume:14 Page:1233-1246
ISSN:1469-5111
Container-title:International Journal of Neuropsychopharmacology
language:en
Short-container-title:

Author:

Barak Segev,Weiner Ina

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Psychiatry and Mental health,Pharmacology

Link

http://academic.oup.com/ijnp/article-pdf/14/9/1233/17486938/14-9-1233.pdf

Reference99 articles.

1. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice;Anagnostaras;Nature Neuroscience,2003

2. The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys;Andersen;Neuropsychopharmacology,2003

3. Modeling cholinergic aspects of schizophrenia: focus on the antimuscarinic syndrome;Barak;Behavioural Brain Research,2009

4. Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia;Barak;Neuropsychopharmacology,2009

5. Physostigmine reverses MK-801-induced but not amphetamine-induced effects on latent inhibition: focus on cholinergic treatments in schizophrenia;Barak;European Neuropsychopharmacology,2006

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials;Schizophrenia Research;2024-12

2. Beyond dopamine: Novel strategies for schizophrenia treatment;Medicinal Research Reviews;2024-04-23

3. Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review;Expert Opinion on Pharmacotherapy;2024-03-03

4. Schizophrenia: from neurochemistry to circuits, symptoms and treatments;Nature Reviews Neurology;2023-12-18

5. Cross-diagnostic determinants of cognitive functioning: the muscarinic cholinergic receptor as a model system;Translational Psychiatry;2023-03-27